CN101468133A - Pharmaceutical composition for treating inflammation of gynecology - Google Patents
Pharmaceutical composition for treating inflammation of gynecology Download PDFInfo
- Publication number
- CN101468133A CN101468133A CNA2007103038585A CN200710303858A CN101468133A CN 101468133 A CN101468133 A CN 101468133A CN A2007103038585 A CNA2007103038585 A CN A2007103038585A CN 200710303858 A CN200710303858 A CN 200710303858A CN 101468133 A CN101468133 A CN 101468133A
- Authority
- CN
- China
- Prior art keywords
- smilacin
- grams
- rhizoma smilacis
- pharmaceutic adjuvant
- smilacis bockii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine preparation for treating gynecological inflammation and preparation method thereof, composed of effective components extracted by the China smilax root and pharmaceutical adjuvant. Various pharmaceutical acceptable preparations for treating gynecological inflammation, such as solid preparation, injection preparation are prepared by mixing the effective components extracted by the China smilax root and pharmaceutical adjuvant. The pharmacological experiment result of the traditional Chinese medicine preparation shows that: the traditional Chinese medicine preparation has good curative effect on treating gynecological inflammation, with better pharmacological effects compared with the commercial drugs.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, be specifically related to a kind of pharmaceutical composition for the treatment of gynecological inflammation.
Background technology
Rhizoma Smilacis Bockii medicine name Rhizoma Smilacis Chinensis has another name called Rhizoma Smilacis Scobinicaulis, belongs to liliaceous plant, and property is sweet, warm, and is nontoxic, can wind-damp dispelling, diuresis, detumescence poison, clinically can be used for treating surgery actute infection, rheumatic arthritis, cancerous protuberance etc.
Gynecological inflammation mainly is meant women genitals's inflammation.Comprise the female vulva inflammation that a variety of causes causes, vaginitis, cervicitis, diseases such as pelvic inflammatory disease, the caused misery of gynecological inflammation has middle hypogastralgia, lumbago, menoxenia, Pruritus, dysmenorrhea, leucorrhea is many, symptoms such as sexual anhedonia, gynecological inflammation is women's commonly encountered diseases, easily send out disease, gynecological inflammation not only can be given a birth because of the woman, artificial abortion, medicine stream and menstrual period, tired, endogenous courses of infection under the situation that body constitution such as operation reduce and getting, also can be unclean because of female article, menstrual period are unhygienic, sterilization does not sternly suffer exogenous courses of infection and suffers from unclean sexual life and the operation process, having a strong impact on women's physical and mental health for a long time, many patients are ashamed of seeking medical advice or not free hospital treatment, affect the state of an illness again and again adversely, so that caused serious consequence. and the treatment of all kinds of gynecological checking be unable to do without medicine for many years always, the application physiotherapy that has in chronic phase, but it is how unsatisfactory on the curative effect. and relapse rate is quite high. and the sickness rate of China's gynaecopathia is 50% (remote segment mountain area, because of after sanitary condition and prevention of water fall to normal price, sickness rate is up to 100%), especially married women suffers from various gynaecopathias in various degree more than 85%.
At present, the clinical treatment gynecological inflammation mainly contains two aspect means, a kind of is that the Western medicine antibiotic is treated, though this method can be alleviated some clinical symptoms, ties up heavily fortified point because some reasons such as the easy recurrent of gynecological inflammation and antibiotic drug resistance cause antibiotic treatment to be taken a step; Another kind is to use Chinese medicine lotion, and the patient's medication in therapeutic process of this method is very difficult, and because most Chinese medicine lotions all have very heavy flavour of a drug, brings huge negative to the patient, thereby cause the compliance of patient's medication poor.
The preparation that is used for now clinical Rhizoma Smilacis Bockii on the market is not a syrup, and the shortcoming of syrup is that to take volume big, and patient's mouthfeel is not well, and is portable and preserve; Number of patent application is that the patent of 03114644 " a kind of granule of ' Jingangteng ' for the treatment of gynaecological inflammation disease and preparation method thereof " set forth with the Rhizoma Smilacis Bockii is that feedstock production becomes granule, the granule of ' Jingangteng ' dose that this patented invention obtains is big, take inconvenience, mouthfeel is relatively poor, and the method for using all is comparatively traditional method, and is relatively poor aspect the patent novelty.
Summary of the invention
For these reasons, our scientific research personnel is by a large amount of scientific researches, find that the effective ingredient smilacin in the Rhizoma Smilacis Bockii can be used for the treatment of gynecological inflammation, again by pharmacy and pharmacological further investigation, the Rhizoma Smilacis Bockii effective ingredient is developed to Chinese medicine preparation, is prepared into soft capsule, drop pill, liquid drugs injection, transfusion, injectable powder, The pharmacological results shows, effect with good treatment gynecological inflammation relatively has better pharmacological action with street drug.
Present technique realizes by following experimental program technology.
A kind of pharmaceutical composition for the treatment of gynecological inflammation, comprise Rhizoma Smilacis Bockii smilacin and pharmaceutic adjuvant, it is characterized in that Rhizoma Smilacis Bockii smilacin 1-10 weight portions, pharmaceutic adjuvant 1-10 weight portions are prepared into soft capsule, drop pill, aqueous injection, infusion solution, injectable powder.
Wherein Rhizoma Smilacis Bockii smilacin content is greater than 90% and less than 100%.
Wherein the soft capsule pharmaceutic adjuvant is vitamin E, glycerol or soybean oil.
Wherein the drop pill pharmaceutic adjuvant is a kind of in Macrogol 4000, the polyethylene glycol 6000.
Wherein the pharmaceutic adjuvant of injection, infusion solution is a kind of of sodium chloride or glucose.
Wherein the injectable powder pharmaceutic adjuvant is mannitol or lactose or sucrose.
Rhizoma Smilacis Bockii smilacin of the present invention can the applying silicon plastic column chromatography or the preparative high-performance liquid chromatographic method obtain, but suitability for industrialized production difficulty, therefore, we have invented a kind of process that is easy to suitability for industrialized production, this method extraction ratio is good, content is high, specific as follows:
Wherein the preparation method of Rhizoma Smilacis Bockii smilacin is:
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, AB-8 or NKA, first water eluting, and eluent discards, reuse concentration is 60%-85% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a kind of in ethyl acetate, butyl acetate, the acetone, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
Two, check and analysis
Adopt high effective liquid chromatography for measuring
Chromatographic column: C
18Reversed phase chromatographic column; Chromatographic condition and system suitability experiment: with the octadecylsilane chemically bonded silica is filler; Flow velocity 1.0ml/min; 25 ℃ of column temperatures;
Experiment medicine: Rhizoma Smilacis Bockii smilacin of the present invention; Smilacin (Chinese medicine bioassay is bought).
Experiment equipment: Tianjin, island company high performance liquid chromatograph
The reference substance preparation: precision takes by weighing smilacin standard substance 10mg, is dissolved in chloroform, and standardize solution is in the 10ml volumetric flask.
The test sample preparation: precision takes by weighing Rhizoma Smilacis Bockii smilacin 10mg of the present invention, is dissolved in chloroform, and standardize solution is in the 10ml volumetric flask.
Algoscopy: accurate respectively absorption reference substance solution and need testing solution respectively inject chromatograph of liquid, adopt by external standard method with calculated by peak area, promptly.
Table 1 Rhizoma Smilacis Bockii smilacin assay
Experiment conclusion: smilacin content of the present invention illustrates that all greater than 90% process of the present invention has realistic meaning.
Three. pharmacology embodiment
Embodiment 1
The mice glacial acetic acid causes turns round the body pain reaction
Experiment medicine: pharmaceutical composition of the present invention; Rhizoma Smilacis Bockii syrup (medicine wholesaling firm in the Temple of the White Dagoba, Beijing buys, and connection pharmaceutical factory produces in the Wuhan City); Glacial acetic acid (Beijing Chemical Plant's production)
Experimental technique: ICR mice, 20 ± 5 grams, respectively are administered once in every morning, afternoon (oral medicine gastric infusion or mouse tail vein administration), the glacial acetic acid of administration in morning next day pneumoretroperitoneum injection 0.7% in 30 minutes, observe the mice pain number of times that 5 minutes endogenous cause of ill pain of mice causes, see Table 2
The comparison of table 2 mouse writhing number of times
Annotate: compare with matched group
*#P＜0.05. is compared with positive controls in P＜0.01
Embodiment 2
Antibacterial experiment in the body
Experiment medicine: pharmaceutical composition of the present invention; Rhizoma Smilacis Bockii syrup (medicine wholesaling firm in the Temple of the White Dagoba, Beijing buys, and connection pharmaceutical factory produces in the Wuhan City);
Experimental technique: the ICR mice, 20 ± 5 grams, the Bacillus proteus intraperitoneal administration infecting mouse with 3000/ml infected after 6 hours, and mortality of mice is observed in administration (oral medicine gastric infusion, the administration of injecting drug use mouse tail vein), sees Table 3:
Table 3 mortality of mice
Annotate: compare with matched group
*#P＜0.05. is compared with positive controls in P＜0.01
Conclusion: show that by pharmacological evaluation Rhizoma Smilacis Bockii smilacin pharmaceutical composition of the present invention has great pharmacological effects, we can learn respectively organize preparation and the comparison of commercially available Rhizoma Smilacis Bockii syrup of the present invention, have stronger pharmacological action.
Four, pharmaceutical composition screening experiment
By above-mentioned pharmacological evaluation, the smilacin effective ingredient is carried out the dose-effect experiment, determine that pharmaceutical composition is: Rhizoma Smilacis Bockii smilacin 1-10 weight portions, pharmaceutic adjuvant 1-10 weight portions.
Five, clinical verification experiment
The preparation of preparation of pharmaceutical compositions of the present invention is used for clinical, combination of oral medication total effective rate wherein of the present invention reaches more than 90%, is higher than Rhizoma Smilacis Bockii syrup (total effective rate 55%); Injectable pharmaceutical compositions total effective rate wherein of the present invention reaches more than 95%, is higher than Rhizoma Smilacis Bockii syrup (total effective rate 55%).
Six, preparation embodiment
Embodiment 1
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, first water eluting, and eluent discards, reuse concentration is 60% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an ethyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 5.0 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and pharmaceutic adjuvant is vitamin E 5.0 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 5.0 grams, and the pharmaceutic adjuvant Macrogol 4000 is 5.0 grams; Injection Rhizoma Smilacis Bockii smilacin is 1.0 grams, and pharmaceutic adjuvant is sodium chloride 1.0 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 1.0 grams, pharmaceutic adjuvant sodium chloride 1.0 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 1.0 grams, and pharmaceutic adjuvant mannitol is 1.0 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 1.0 grams, and pharmaceutic adjuvant mannitol is 1.0 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 2
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is AB-8, first water eluting, and eluent discards, reuse concentration is 85% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a butyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 10.0 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and pharmaceutic adjuvant glycerol is 10.0 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 10.0 grams, and the pharmaceutic adjuvant polyethylene glycol 6000 is 10.0 grams; Injection Rhizoma Smilacis Bockii smilacin is 6.0 grams, and the pharmaceutic adjuvant glucose is 6.0 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 6.0 grams, and the pharmaceutic adjuvant glucose is 6.0 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 6.0 grams, and the pharmaceutic adjuvant lactose is 6.0 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 6.0 grams, and the pharmaceutic adjuvant lactose is 6.0 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 3
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is NKA, first water eluting, and eluent discards, reuse concentration is 75% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an acetone, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 6.2 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and the pharmaceutic adjuvant soybean oil is 6.2 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 6.2 grams, and the pharmaceutic adjuvant polyethylene glycol 6000 is 6.2 grams; Injection Rhizoma Smilacis Bockii smilacin is 5.8 grams, and pharmaceutic adjuvant sodium chloride is 5.8 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 5.8 grams, and the pharmaceutic adjuvant glucose is 5.8 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 5.8 grams, and pharmaceutic adjuvant mannitol is 5.8 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 5.8 grams, and pharmaceutic adjuvant sucrose is 5.8 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 4
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, first water eluting, and eluent discards, reuse concentration is 60% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an ethyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 1 gram that soft capsule has the Rhizoma Smilacis Bockii smilacin, pharmaceutic adjuvant soybean oil 10 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 1 gram, and the pharmaceutic adjuvant Macrogol 4000 is 10 grams; Injection Rhizoma Smilacis Bockii smilacin is 1 gram, and the pharmaceutic adjuvant glucose is 10 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 1 gram, and pharmaceutic adjuvant sodium chloride is 10 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 1 gram, and pharmaceutic adjuvant sucrose is 10 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 1 gram, and the pharmaceutic adjuvant lactose is 10 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 5
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is NKA, first water eluting, and eluent discards, reuse concentration is 65% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a butyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 10 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and the pharmaceutic adjuvant vitamin E is 1 gram; Drop pill Rhizoma Smilacis Bockii smilacin is 10 grams, and the pharmaceutic adjuvant Macrogol 4000 is 1 gram; Injection Rhizoma Smilacis Bockii smilacin is 10 grams, and pharmaceutic adjuvant sodium chloride is 1 gram; Infusion solutions Rhizoma Smilacis Bockii smilacin is 10 grams, and pharmaceutic adjuvant sodium chloride is 1 gram; Injectable powder Rhizoma Smilacis Bockii smilacin is 10 grams, and the pharmaceutic adjuvant lactose is 1 gram; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 10 grams, and pharmaceutic adjuvant mannitol is 1 gram.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 6
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, first water eluting, and eluent discards, reuse concentration is 60% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an ethyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 2 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and pharmaceutic adjuvant is vitamin E 8 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 2 grams, and the pharmaceutic adjuvant Macrogol 4000 is 8 grams; Injection Rhizoma Smilacis Bockii smilacin is 2 grams, and pharmaceutic adjuvant is sodium chloride 8 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 2 grams, pharmaceutic adjuvant sodium chloride 2 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 2 grams, and pharmaceutic adjuvant mannitol is 8 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 2 grams, and pharmaceutic adjuvant mannitol is 8 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 7
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is AB-8, first water eluting, and eluent discards, reuse concentration is 85% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a butyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 7 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and pharmaceutic adjuvant glycerol is 3 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 7 grams, and the pharmaceutic adjuvant polyethylene glycol 6000 is 3 grams; Injection Rhizoma Smilacis Bockii smilacin is 7 grams, and the pharmaceutic adjuvant glucose is 3 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 7 grams, and the pharmaceutic adjuvant glucose is 3 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 7 grams, and the pharmaceutic adjuvant lactose is 3 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 7 grams, and the pharmaceutic adjuvant lactose is 3 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 8
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is NKA, first water eluting, and eluent discards, reuse concentration is 75% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an acetone, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 3.5 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and the pharmaceutic adjuvant soybean oil is 6.8 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 3.5 grams, and the pharmaceutic adjuvant polyethylene glycol 6000 is 6.8 grams; Injection Rhizoma Smilacis Bockii smilacin is 3.5 grams, and pharmaceutic adjuvant sodium chloride is 6.8 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 3.5 grams, and the pharmaceutic adjuvant glucose is 6.8 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 3.5 grams, and pharmaceutic adjuvant mannitol is 6.8 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 3.5 grams, and pharmaceutic adjuvant sucrose is 6.8 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 9
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, first water eluting, and eluent discards, reuse concentration is 60% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an ethyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 4 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, pharmaceutic adjuvant soybean oil 6 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 4 grams, and the pharmaceutic adjuvant Macrogol 4000 is 6 grams; Injection Rhizoma Smilacis Bockii smilacin is 4 grams, and the pharmaceutic adjuvant glucose is 6 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 4 grams, and pharmaceutic adjuvant sodium chloride is 6 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 4 grams, and pharmaceutic adjuvant sucrose is 6 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 4 grams, and the pharmaceutic adjuvant lactose is 6 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 10
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is NKA, first water eluting, and eluent discards, reuse concentration is 65% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a butyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 10 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and the pharmaceutic adjuvant vitamin E is 10 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 10 grams, and the pharmaceutic adjuvant Macrogol 4000 is 10 grams; Injection Rhizoma Smilacis Bockii smilacin is 10 grams, and pharmaceutic adjuvant sodium chloride is 10 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 10 grams, and pharmaceutic adjuvant sodium chloride is 10 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 10 grams, and the pharmaceutic adjuvant lactose is 10 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 10 grams, and pharmaceutic adjuvant mannitol is 10 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 11
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, first water eluting, and eluent discards, reuse concentration is 60% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is an ethyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 7.5 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and pharmaceutic adjuvant is vitamin E 3 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 7.5 grams, and the pharmaceutic adjuvant Macrogol 4000 is 3 grams; Injection Rhizoma Smilacis Bockii smilacin is 7.5 grams, and pharmaceutic adjuvant is sodium chloride 3 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 7.5 grams, pharmaceutic adjuvant sodium chloride 3 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 7.5 grams, and pharmaceutic adjuvant mannitol is 3 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 7.5 grams, and pharmaceutic adjuvant mannitol is 3 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 1000 of 1000 of soft capsules or 10000 of drop pill or 1000 of aqueous injection or 1000 of infusion solutions or 1000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Embodiment 12
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is AB-8, first water eluting, and eluent discards, reuse concentration is 85% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a butyl acetate, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
It is 76 grams that soft capsule has the Rhizoma Smilacis Bockii smilacin, and pharmaceutic adjuvant glycerol is 33 grams; Drop pill Rhizoma Smilacis Bockii smilacin is 76 grams, and the pharmaceutic adjuvant polyethylene glycol 6000 is 33 grams; Injection Rhizoma Smilacis Bockii smilacin is 76 grams, and the pharmaceutic adjuvant glucose is 33 grams; Infusion solutions Rhizoma Smilacis Bockii smilacin is 76 grams, and the pharmaceutic adjuvant glucose is 33 grams; Injectable powder Rhizoma Smilacis Bockii smilacin is 76 grams, and the pharmaceutic adjuvant lactose is 33 grams; Lyophilized injectable powder Rhizoma Smilacis Bockii smilacin is 73 grams, and the pharmaceutic adjuvant lactose is 33 grams.
Get the Rhizoma Smilacis Bockii smilacin and mix, prepare 10000 of 10000 of soft capsules or 100000 of drop pill or 10000 of aqueous injection or 10000 of infusion solutions or 10000 of injectable powder or lyophilized injectable powders according to the pharmaceutics basic demand with pharmaceutic adjuvant.
Annotate: the present invention's concrete technical scheme required for protection is not limited to the concrete combination of the expressed technical scheme of the foregoing description.
Claims (7)
1, a kind of pharmaceutical composition for the treatment of gynecological inflammation, comprise Rhizoma Smilacis Bockii smilacin and pharmaceutic adjuvant, it is characterized in that Rhizoma Smilacis Bockii smilacin 1-10 weight portions, pharmaceutic adjuvant 1-10 weight portions are prepared into soft capsule, drop pill, aqueous injection, infusion solution, injectable powder.
2, a kind of pharmaceutical composition for the treatment of gynecological inflammation according to claim 1, wherein Rhizoma Smilacis Bockii smilacin content is greater than 90% and less than 100%.
3, according to claim 1. a kind of pharmaceutical composition for the treatment of gynecological inflammation, wherein the preparation method of Rhizoma Smilacis Bockii smilacin is:
Get the Rhizoma Smilacis Bockii decoction pieces, extracting in water filters extracting solution, concentrates, concentrated solution adds ethanol, leaves standstill macroporous adsorptive resins on the supernatant, macroporous adsorbent resin is D101, AB-8 or NKA, first water eluting, and eluent discards, reuse concentration is 60%-85% ethanol elution, merges eluent, reclaims ethanol to most, add organic solvent extraction, organic solvent is a kind of in ethyl acetate, butyl acetate, the acetone, keeps organic facies, reclaim organic solvent to most, drying obtains smilacin.
4, a kind of pharmaceutical composition for the treatment of gynecological inflammation according to claim 1, wherein the soft capsule pharmaceutic adjuvant is vitamin E, glycerol or soybean oil.
5, a kind of pharmaceutical composition for the treatment of gynecological inflammation according to claim 1, wherein the drop pill pharmaceutic adjuvant is a kind of in Macrogol 4000, the polyethylene glycol 6000.
6, a kind of pharmaceutical composition for the treatment of gynecological inflammation according to claim 1, wherein the pharmaceutic adjuvant of injection, infusion solution is a kind of of sodium chloride or glucose.
7, a kind of pharmaceutical composition for the treatment of gynecological inflammation according to claim 1, wherein the injectable powder pharmaceutic adjuvant is mannitol or lactose or sucrose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007103038585A CN101468133A (en) | 2007-12-26 | 2007-12-26 | Pharmaceutical composition for treating inflammation of gynecology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007103038585A CN101468133A (en) | 2007-12-26 | 2007-12-26 | Pharmaceutical composition for treating inflammation of gynecology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101468133A true CN101468133A (en) | 2009-07-01 |
Family
ID=40826096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007103038585A Pending CN101468133A (en) | 2007-12-26 | 2007-12-26 | Pharmaceutical composition for treating inflammation of gynecology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101468133A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103897072A (en) * | 2012-12-27 | 2014-07-02 | 成都立力医药科技有限公司 | Bock greenbrier rhizome polysaccharide extract and preparation method thereof |
| CN105193825A (en) * | 2015-10-18 | 2015-12-30 | 苏州普罗达生物科技有限公司 | Application of sarsasapogenin 3-hydroxyl formyl ester to preparation of drug for treating cervicitis |
| CN105963687A (en) * | 2016-04-27 | 2016-09-28 | 张金凤 | Compound preparation for treating chronic pelvic pain and preparation method of compound preparation |
-
2007
- 2007-12-26 CN CNA2007103038585A patent/CN101468133A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103897072A (en) * | 2012-12-27 | 2014-07-02 | 成都立力医药科技有限公司 | Bock greenbrier rhizome polysaccharide extract and preparation method thereof |
| CN103897072B (en) * | 2012-12-27 | 2016-08-31 | 成都立力医药科技有限公司 | A kind of Rhizoma Smilacis Bockii polyoses extract and preparation method thereof |
| CN105193825A (en) * | 2015-10-18 | 2015-12-30 | 苏州普罗达生物科技有限公司 | Application of sarsasapogenin 3-hydroxyl formyl ester to preparation of drug for treating cervicitis |
| CN105963687A (en) * | 2016-04-27 | 2016-09-28 | 张金凤 | Compound preparation for treating chronic pelvic pain and preparation method of compound preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457139C (en) | Method for preparing a Shuanhuanglian injection and the component detecting method | |
| CN101711805B (en) | Medicine composition for treating rheumatoid arthritis and preparation thereof | |
| WO2004024172A1 (en) | Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug | |
| WO2016107579A1 (en) | Preparation and application of flavonol as brain-targeting synergist | |
| CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN101468133A (en) | Pharmaceutical composition for treating inflammation of gynecology | |
| CN1883566B (en) | Anti-inflammation medicine and method for preparing same | |
| CN101559066B (en) | Use of beta-galactosides and composition in preparing medicine for myocardial ischemia | |
| CN1973853B (en) | Hemostatic and analgetic medicine composition and its preparation process | |
| CN100431594C (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN1836665B (en) | Pharmaceutical uses of hesperidin or its composition | |
| CN100453080C (en) | Lindera root alkaloid, its preparation method and application in medicine preparation | |
| CN102784157A (en) | Application of slender dioscin and pharmaceutical composition containing the same | |
| CN1872083B (en) | Application of monarda glycoside in preparing medicine for treating or preventing hemorrhagic disease | |
| CN102614248B (en) | Traditional Chinese herbal composite for treating stroke and chest obstruction | |
| CN101375954B (en) | Medicament composition, preparation method thereof and use | |
| CN103191243B (en) | Application of medicament composition composed of coptis chinensis and fructus evodiae and preparation method of medicament composition | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN100384431C (en) | Traditional Chinese medicine compositions | |
| CN101569656B (en) | Traditional Chinese medicine preparation and preparation method thereof | |
| CN1943584B (en) | Medicinal composition for treating cardio-cerebral vascular disease and its preparing method | |
| CN103735689A (en) | Application of natural medicinal composition in preparing anti-hypoxia medicines and health-care products | |
| CN103880913A (en) | Compound with liver protection effect and application thereof | |
| CN101940585A (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090701 |